CA2505479A1 - Interactions moleculaires dans des neurones - Google Patents

Interactions moleculaires dans des neurones Download PDF

Info

Publication number
CA2505479A1
CA2505479A1 CA002505479A CA2505479A CA2505479A1 CA 2505479 A1 CA2505479 A1 CA 2505479A1 CA 002505479 A CA002505479 A CA 002505479A CA 2505479 A CA2505479 A CA 2505479A CA 2505479 A1 CA2505479 A1 CA 2505479A1
Authority
CA
Canada
Prior art keywords
pdz
polypeptide
protein
binding
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002505479A
Other languages
English (en)
Inventor
Peter S. Lu
Jonathan David Garman
Michael P. Belmares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbor Vita Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2505479A1 publication Critical patent/CA2505479A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs perturbant la liaison entre une protéine PDZ et des ligands associés, notamment des récepteurs de N-méthyle-D-aspartate, impliqués dans des troubles neurologiques variés. L'invention concerne des compositions pharmaceutiques contenant ces inhibiteurs, et leur utilisation dans le traitement de maladies neurologiques, notamment l'accident vasculaire cérébral et l'ischémie. L'invention concerne des méthodes de criblage permettant d'identifier des inhibiteurs supplémentaires d'interactions de ligands protéiniques spécifiques avec des protéines PDZ.
CA002505479A 2002-11-14 2003-11-14 Interactions moleculaires dans des neurones Abandoned CA2505479A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42621302P 2002-11-14 2002-11-14
US42621202P 2002-11-14 2002-11-14
US60/426,213 2002-11-14
US60/426,212 2002-11-14
PCT/US2003/036698 WO2004045535A2 (fr) 2002-11-14 2003-11-14 Interactions moleculaires dans des neurones

Publications (1)

Publication Number Publication Date
CA2505479A1 true CA2505479A1 (fr) 2004-06-03

Family

ID=32329101

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002505479A Abandoned CA2505479A1 (fr) 2002-11-14 2003-11-14 Interactions moleculaires dans des neurones

Country Status (3)

Country Link
EP (1) EP1578365A4 (fr)
CA (1) CA2505479A1 (fr)
WO (1) WO2004045535A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7858322B2 (en) 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2613012A1 (fr) 2005-06-23 2007-01-04 Arbor Vita Corporation Procedes et compositions de modulation de la cox
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
JP5746468B2 (ja) * 2006-07-11 2015-07-08 ノノ インコーポレイテッド 発熱を伴う脳卒中を処置する方法および組成物
EP1884521A1 (fr) * 2006-07-31 2008-02-06 Xigen S.A. Peptide de fusion pour inhiber l'interaction du récepteur neuronal NMDA (NMDAR) avec les protéines interagissant avec le récepteur NMDA
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
CA2765171C (fr) * 2009-06-10 2018-10-02 Nono Inc. Co-administration d'un agent lie a un peptide d'internalisation avec un anti-inflammatoire
BRPI1010718A2 (pt) * 2009-06-10 2016-03-15 Nono Inc sistemas modelo e regimes de tratamento para tratar doença neurológica.
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
WO2012048721A1 (fr) 2010-10-14 2012-04-19 Xigen S.A. Utilisation d'inhibiteurs peptidiques, aptes à pénétrer dans les cellules, de la voie de transduction du signal jnk pour le traitement de maladies oculaires inflammatoires chroniques ou non-chroniques
EP2581384A1 (fr) * 2011-10-11 2013-04-17 Institut Pasteur Produits utiles pour le traitement des tumeurs malignes du système nerveux humain
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
CN106554386A (zh) * 2015-09-25 2017-04-05 广州恒上医药技术有限公司 人***瘤病毒的表位肽及其应用
EP3723781A4 (fr) 2017-12-13 2021-07-21 The Research Foundation for the State University of New York Peptides et autres agents pour traiter la douleur et augmenter la sensibilité à la douleur
CN114807142B (zh) * 2022-05-26 2024-03-29 源生生物科技(青岛)有限责任公司 一种环状RNA-circ-Magi1及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014303A2 (fr) * 2001-08-03 2003-02-20 Arbor Vita Corporation Interactions moleculaires dans les cellules
CA2273622C (fr) * 1999-06-02 2012-03-20 Michael Tymianski Inhibition de la signalisation induite par le recepteur nmda dans le but de reduire les lesions neuronales
AU2001277986A1 (en) * 2000-07-25 2002-02-05 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
EP1351980B1 (fr) * 2001-01-18 2014-12-31 The Board Of Trustees Of The Leland Stanford Junior University Peptides destines a l'activation et a l'inhibition de of delta pkc
JP3536039B2 (ja) * 2001-05-08 2004-06-07 独立行政法人 科学技術振興機構 Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ

Also Published As

Publication number Publication date
EP1578365A2 (fr) 2005-09-28
EP1578365A4 (fr) 2009-09-23
WO2004045535A3 (fr) 2006-07-13
WO2004045535A2 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
US20110039758A1 (en) Molecular Interactions in Neurons
CA2505479A1 (fr) Interactions moleculaires dans des neurones
US7858322B2 (en) Method of determining inhibition of binding to TRPM7 protein
US20090075377A1 (en) Molecular interactions in cells
CA2457424A1 (fr) Interactions moleculaires dans les cellules
US7972774B2 (en) Methods of diagnosing cervical cancer
US20100120700A1 (en) Methods and compositions for treating cervical cancer
US20050019841A1 (en) Modulation of signaling pathways
US7514224B2 (en) Arrays of PDZ domain polypeptides
AU2008258186A1 (en) Methods of diagnosing cervical cancer
US20120093873A1 (en) Molecular Interactions in Hematopoietic Cells
US20050282743A1 (en) Molecular interactions in cells
JP2009503439A (ja) ウイルス感染および細菌感染の診断および処置のための方法および組成物
US7919584B1 (en) Methods and compositions for diagnosis and treatment of asthma
AU2003291558B2 (en) Molecular interactions in neurons
WO2002031512A2 (fr) Interactions moleculaires dans des cellules hematopoietiques
EP1599214A2 (fr) Methodes et compositions destinees a traiter le cancer du col uterin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued